Worldwide Regenerative Medicine Outlook to 2027: Therapeutics Segment Dominated the Market in 2020 Due to the High Usage of Primary Cell-Based Therapies

News provided by

Dec 29, 2021, 09:30 ET

DUBLIN, Dec. 29, 2021 /PRNewswire/ -- The "Global Regenerative Medicine Market Size, Share & Trends Analysis Report by Product (Cell-based Immunotherapies, Gene Therapies), by Therapeutic Category (Cardiovascular, Oncology), and Segment Forecasts, 2021-2027" report has been added to ResearchAndMarkets.com's offering.

The global regenerative medicine market size is expected to reach USD 57.08 billion by 2027, growing at a CAGR of 11.27% over the forecast period.

Recent advancements in biological therapies have resulted in a gradual shift in preference toward personalized medicinal strategies over the conventional treatment approach. This has resulted in rising R&D activities in the regenerative medicine arena for the development of novel regenerative therapies.

Furthermore, advancements in cell biology, genomics research, and gene-editing technology are anticipated to fuel the growth of the industry. Stem cell-based regenerative therapies are in clinical trials, which may help restore damaged specialized cells in many serious and fatal diseases, such as cancer, Alzheimer's, neurodegenerative diseases, and spinal cord injuries.

For instance, various research institutes have adopted Human Embryonic Stem Cells (hESCs) to develop a treatment for Age-related Macular Degeneration (AMD).

Constant advancements in molecular medicines have led to the development of gene-based therapy, which utilizes targeted delivery of DNA as a medicine to fight against various disorders.

Gene therapy developments are high in oncology due to the rising prevalence and genetically driven pathophysiology of cancer. The steady commercial success of gene therapies is expected to accelerate the growth of the global market over the forecast period.

Regenerative Medicine Market Report Highlights

The number of companies engaged in the development of advanced therapies is continuously increasing over the past few years. This is anticipated to increase the competition among companies to create a specific and efficient pipeline
The therapeutics segment dominated the market in 2020 due to the high usage of primary cell-based therapies along with advances in stem cell and progenitor cell therapies. The implementation of these therapies in dermatological, musculoskeletal, and dental application results in the highest share of this segment
Stem cell and progenitor cell-based therapies are anticipated to witness rapid growth due to high investments in this research space and an increasing number of stem cell banks
With the rise in R&D and clinical trials of regenerative medicines, key players are offering several consulting services leading to lucrative growth of the services segment
The oncology segment is estimated to account for the largest revenue share by 2027 owing to the high prevalence of cancer indications, which drives the demand for better solutions. The presence of a strong pipeline of regenerative medicines for cancer treatment also supplements the segment growth
North America dominated the market in 2020 and is projected to continue its dominance over the forecast period. A significant number of universities and research organizations investigating various stem cell-based approaches for regenerative apposition in the U.S. propels the region's growth
Asia Pacific is projected to witness the fastest CAGR over the forecast period due to the emergence of key players and rapid adoption of cell-based approaches in the healthcare

Key Topics Covered:

Market Variables, Trends, & Scope

Market Driver Analysis
Presence of a strong pipeline and a large number of clinical trials
High economic impact of regenerative medicine
Emerging applications of gene therapy in regenerative medicine
Increasing government & private funding to support the development of regenerative medicine
Technological advancements in regenerative medicine (stem cell, tissue engineering, and nanotechnology)
Increase in strategic partnerships to accelerate development & commercialization of regenerative medicines
Rising prevalence of chronic diseases & genetic disorders, degenerative diseases, and bone & joint diseases leading to rise in demand for regenerative treatments
Market Restraint Analysis
High cost of treatment
Regulatory issues pertaining to stem cells, tissues engineering, and regenerative medicines
Market Challenge Analysis
Current challenges of on-market gene therapies
Penetration & Growth Prospect Mapping for Therapeutic Category, 2020
Reimbursement Framework
Reimbursement Framework & Clinical Translation of RM
Reimbursement Framework for RM: Europe
Reimbursement Framework for RM: South Korea
Technology Overview
Autologous Cell Transplantation
Next-Generation Cell-Based Therapies
CAR-T Cell Technologies
Cost Structure Analysis
User Perspective Analysis
Market Influencer Analysis
Consumer Behavior Analysis
Regenerative Medicine Market - SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
Industry Analysis - Porter's
Regenerative Medicine Market Analysis Tools
Major Deals & Strategic Alliances Analysis
Merger & Acquisition Deals
Collaboration & Partnerships
Business Expansion
Market Entry Strategies
Pharmaceutical and biotechnology companies
Raw material supplier
Contract Service Provider
Distributor
Companion Diagnostics companies:
Case Studies
MACI (Vericel Corporation):
LAVIV (Azficel-T) (Fibrocell Technologies):

Competitive Analysis

Covid-19 Impact Analysis

COVID-19 Impact Analysis
Challenges Analysis
Manufacturing & Supply Challenges
Opportunities analysis
Need For Development Of New Therapies Against SARS-COV-2
T-cell Therapy
Cell Therapy
Gene Therapy
Tissue engineering
Rise In Demand For Supply Chain Management Solutions
Challenges in Manufacturing T-cell Therapies Against COVID-19
Clinical Trial Analysis

Regenerative Medicine Market: Product Business Analysis

Regenerative Medicine Market: Therapeutic Category Business Analysis

Regenerative Medicine Market: Regional Business Analysis

Companies Mentioned

Integra Lifesciences Corporation
Astellas Pharma Inc.
Cook Biotech, Inc.
Bayer AG
Astrazeneca plc
F. Hoffmann-La Roche Ltd.
Pfizer, Inc.
Merck Kgaa
Abbott
Vericel Corporation
Novartis AG
GlaxoSmithKline plc.
Baxter International Inc.
Boehringer Ingelheim GmbH
Amgen Inc.
Cesca Therapeutics Inc. / Thermogenesis Holdings Inc.
U.S Stem Cell, Inc.
Bristol-Myers Squibb Company
Eli Lilly and Company
Nuvasive, Inc.
Organogenesis, Inc.
Mimedx Group, Inc.
Takara Bio Inc.
Osiris Therapeutics, Inc.
Corline Biomedical Ab

For more information about this report visit https://www.researchandmarkets.com/r/ma7vcs

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets